Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

QH104

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Beijing Qinghui Liannuo Biotechnology, Suzhou Dushu Lake Hospital

Drug class:

γδ TCR modulator, B7-H3-targeted CAR-T immunotherapy

Related drugs:

‹

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)

SC-CAR4BRAIN (0)

Undisclosed EGFR/B7H3 CAR-T (0)

fhB7H3.CAR-Ts (0)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

BTN2A1/3A1-Fc-CD19scFv (0)

CD7-UCAR-γδT cells (0)

ET1402L1-ARTEMIS T cells (0)

Gamma delta T-cells (0)

autologous γδ T lymphocytes (0)

ALEXIS-ISO-1 (0)

NK/γδ T cell-enriched cell therapy (0)

PF-08046052 (0)

anti-CD19-CAR γδT (0)

γδT Cell infusion (0)

γδT Cell infusion agent (0)

B7-H3 CAR-T (0)

CAR.B7-H3 T (0)

CD276 CAR-T (0)

GD2, PSMA and CD276 CAR-T (0)

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)

SC-CAR4BRAIN (0)

Undisclosed EGFR/B7H3 CAR-T (0)

fhB7H3.CAR-Ts (0)

›